Search Result

Results for "

Hypoxia-inducible factor inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HIF/HIF Prolyl-Hydroxylase (50) ADC Cytotoxin (2) Akt (1) Antibiotic (7) Apoptosis (10) Bacterial (5) Calcium Channel (4) Ferroptosis (4) Fungal (2) HSP (2) Influenza Virus (2) Isotope-Labeled Compounds (1) MDM-2/p53 (4) MicroRNA (2) mTOR (1) Potassium Channel (4) TAM Receptor (1) Topoisomerase (2) VEGFR (2)
By Research Areas:	Cancer (37) Cardiovascular Disease (12) Infection (9) Inflammation/Immunology (7) Metabolic Disease (10) Neurological Disease (5)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: HIF/HIF Prolyl-Hydroxylase Salt-inducible Kinase (SIK) Itk AIM2

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15836

BAY 87-2243 20+ Cited Publications	HIF/HIF Prolyl-Hydroxylase Ferroptosis	Cancer
BAY 87-2243 is a highly potent and selective hypoxia-inducible factor-1 (HIF-1) inhibitor.

HY-141625

TRC160334	HIF/HIF Prolyl-Hydroxylase	Others
TRC160334 is a hypoxia-inducible factor (HIF) hydroxylase inhibitor. TRC160334 can be used for the research of ischemia/reperfusion injury .

HY-111387

IDF-11774 5 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
IDF-11774 is a novel hypoxia-inducible factor α (HIFα)-1 inhibitor with an IC₅₀ of 3.65 μM.

HY-109057

Enarodustat 3 Publications Verification JTZ-951; SAL0951	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease
Enarodustat is a potent and orally active hypoxia-inducible factor prolyl hydroxylase inhibitor, with an EC₅₀ of 0.22 μM. Enarodustat has the potential for renal anemia treatment.

HY-17608

Daprodustat 10+ Cited Publications GSK1278863	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Daprodustat (GSK1278863) is an orally active hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor being developed for the treatment of anemia associated with chronic kidney disease.

HY-101023

MK-8617 3 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology
MK-8617 is an orally active pan-inhibitor of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) with an IC₅₀ of 1 nM for PHD2.

HY-101449

Adaptaquin 1 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease
Adaptaquin is an inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PHD2), with an IC₅₀ of 2 μM. Adaptaquin can inhibit lipid peroxidation and maintain mitochondrial function .

HY-N12041

Axl-IN-16	TAM Receptor HIF/HIF Prolyl-Hydroxylase	Cancer
Axl-IN-16 is a dual inhibitor of Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression .

HY-141625A

TRC160334 sodium	HIF/HIF Prolyl-Hydroxylase	Others
TRC160334 sodium is a hypoxia-inducible factor (HIF) hydroxylase inhibitor. TRC160334 sodium can be used for the research of ischemia/reperfusion injury .

HY-N10330

7-Hydroxyneolamellarin A	HIF/HIF Prolyl-Hydroxylase VEGFR	Cancer
7-Hydroxyneolamellarin A is a natural product that could be derived from sponge Dendrilla nigra. 7-Hydroxyneolamellarin A is a potent hypoxia-inducible factor-1α (HIF-1α) inhibitor. 7-Hydroxyneolamellarin A attenuates the accumulation of hypoxia-inducible factor-1α (HIF-1α) protein and inhibits vascular epidermal growth factor (VEGF) transcriptional activity. 7-Hydroxyneolamellarin A can be used in research of cancer .

HY-139287

M1002 1 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
M1002 is a **hypoxia-inducible factor-2 (HIF-2*) agonist, and can enhance the expression of HIF-2 target genes. M1002 shows synergy with prolyl-hydroxylase domain (PHD) inhibitors* .

HY-13426

Roxadustat Maximum Cited Publications 39 Publications Verification FG-4592	HIF/HIF Prolyl-Hydroxylase Ferroptosis	Cancer
Roxadustat is an orally active hypoxia-inducible factor (HIF) prolyl-hydroxylase (PHD) inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin .

HY-106101

Echinomycin 4 Publications Verification Quinomycin A; NSC-13502	HIF/HIF Prolyl-Hydroxylase Antibiotic Bacterial	Cancer
Echinomycin (Quinomycin A) is potent small-molecule and cell-permeable inhibitor of hypoxia-inducible factor-1 (HIF-1) DNA-binding activity. Echinomycin selectively inhibits the cancer stem cells (CSCs) with an IC₅₀ of 29.4 pM .

HY-121728

Langkamide	Others	Others
Langkamide is a novel hypoxia-inducible factor-2 (HIF-2) inhibitory pyrrolidone alkaloid isolated from the roots and stems of Piper sarmentosum, which inhibits HIF-2 transcriptional activity with an EC?? value of 14.0μM.

HY-117479

CL67	HIF/HIF Prolyl-Hydroxylase	Cancer
CL67 is a potent hypoxia-inducible factor (HIF) pathway inhibitor. CL67 interferes G-quadruplex structures within promoter sequences. CL67 can be used in research of renal cancer .

HY-108697A

(Rac)-PT2399	HIF/HIF Prolyl-Hydroxylase	Cancer
(Rac)-PT2399 (Compound 10e), the racemate of PT2399, acts as a potent and specific hypoxia-inducible factor 2a (HIF-2α) inhibitor with an IC₅₀ of 0.01 μM .

HY-113662

CLB-016	HIF/HIF Prolyl-Hydroxylase	Cancer
CLB-016 is a potent Hypoxia-inducible factor (HIF-1) inhibitor with an IC₅₀ of 19.1 μM. CLB-016 significantly suppresses HIF-1-mediated hypoxia response .

HY-101277

Vadadustat 5+ Cited Publications PG-1016548; AKB-6548	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor . Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo .

HY-13426S

Roxadustat-d5	HIF/HIF Prolyl-Hydroxylase Ferroptosis	Cancer
Roxadustat-d₅ is deuterium labeled Roxadustat. Roxadustat is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin[1].

HY-15672

FM19G11	HIF/HIF Prolyl-Hydroxylase	Neurological Disease Cancer
FM19G11 is a hypoxia-inducible factor-1-alpha (HIF-1α) inhibitor, and it inhibits hypoxia-induced luciferase activity with an IC₅₀ of 80 nM in HeLa cells. FM19G11 modulates other signaling pathways, including mTOR and PI3K/Akt/eNOS, when the HIF-1α pathway is inactivated under normoxic conditions .

HY-131346

HIF-PHD-IN-1	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
HIF-PHD-IN-1 is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD), with an IC₅₀ of 54 nM for hHIF-PHD2. HIF-PHD-IN-1 is promising therapeutic agents for renal anemia .

HY-17608R

Daprodustat (Standard)	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Daprodustat (Standard) is the analytical standard of Daprodustat. This product is intended for research and analytical applications. Daprodustat (GSK1278863) is an orally active hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor being developed for the treatment of anemia associated with chronic kidney disease.

HY-18259

103D5R	HIF/HIF Prolyl-Hydroxylase	Cancer
103D5R (Compound 15) is an inhibitor for the activation of **hypoxia-inducible factor-1 (HIF-1) with an IC₅₀** of 35 µM, through reduction of the HIF-1α protein synthesis. 103D5R inhibits the proliferation of LN229 with IC₅₀ of 26 µM .

HY-130264

HIF-2α-IN-2	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-2 is a hypoxia-inducible factors (HIF-2α) inhibitor extracted from patent WO2015035223A1, Compound 232, has an IC₅₀ of 16 nM in scintillation proximity assay (SPA) .

HY-B2171A

Carubicin hydrochloride Carminomycin hydrochloride; Carminomicin I hydrochloride	Apoptosis	Infection Cancer
Carubicin hydrochloride is a microbially-derived compound. Carubicin hydrochloride is an effective inhibitor of VHL-defective (VHL−/−) CCRCC cell proliferation. Carubicin hydrochloride also induces apoptosis by a mechanism independent of p53 or hypoxia-inducible factor HIF2. Carubicin hydrochloride has the potential for the research of cancer diseases .

HY-163839

DS-1093a	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease
DS-1093a is an orally active hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitor, with an EC₅₀ of 0.49 μM in Hep3B cell EPO production. DS-1093a can be used in the research of renal anemia .

HY-B2171

Carubicin Carminomycin; Carminomicin I	Apoptosis	Infection Cancer
Carubicin (Carminomycin) is a microbially-derived compound. Carubicin is an effective inhibitor of VHL-defective (VHL−/−) CCRCC cell proliferation. Carubicin also induces apoptosis by a mechanism independent of p53 or hypoxia-inducible factor HIF2. Carubicin has the potential for the research of cancer diseases .

HY-13426R

Roxadustat (Standard)	HIF/HIF Prolyl-Hydroxylase Ferroptosis	Cancer
Roxadustat (Standard) is the analytical standard of Roxadustat. This product is intended for research and analytical applications. Roxadustat is an orally active hypoxia-inducible factor (HIF) prolyl-hydroxylase (PHD) inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin .

HY-112144

TP0463518 1 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease
TP0463518 is a potent hypoxia-inducible factor prolyl hydroxylases (PHDs) inhibitor with a K_i value of 5.3 nM for human PHD2. TP0463518 also inhibits human PHD1/PHD3 with IC₅₀s of 18 and 63 nM as well as monkey PHD2 with an IC₅₀ value of 22 nM .

HY-146144

HIF-IN-1	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-IN-1 (Compound 3c) is a hypoxia-inducible factor (HIF)-1 inhibitor. HIF-IN-1 suppresses HIF-1α protein accumulation without affecting the levels of HIF-1α mRNA. HIF-IN-1 shows no obvious cytotoxicity .

HY-168533

ZG-2305	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease
ZG-2305 is a potent, orally active and selective factor inhibiting hypoxia-inducible factor (FIH) inhibitor with K_i values of 79.6, 2786 nM for FIH, PHD2, respectively. ZG-2305 increases the expression of EGLN3 gene. ZG-2305 decreases the cellular triglycerides levels and reduces lipid accumulation. ZG-2305 has the potential for the research of obesity and fatty liver disease .

HY-16560

Camptothecin Maximum Cited Publications 39 Publications Verification Campathecin; (S)-(+)-Camptothecin; CPT	Topoisomerase ADC Cytotoxin MicroRNA Influenza Virus Apoptosis Fungal Antibiotic	Infection Cancer
Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM . Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells .

HY-107553

Chetomin	HSP Apoptosis	Cancer
Chetomin, an active component of Chaetomium globosum, is a heat shock protein 90/hypoxia-inducible factor 1 alpha (Hsp90/HIF1α) pathway inhibitor. Chetomin is a potent, nontoxic non-small cell lung cancer cancer stem cells (NSCLC CSC)-targeting molecule .

HY-W747868

Molidustat sodium	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Molidustat sodium is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC₅₀ values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat sodium can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat sodium can be utilized in the research of renal anemia .

HY-12654

Molidustat 5+ Cited Publications BAY 85-3934	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Molidustat (BAY 85-3934) is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC₅₀ values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat can be utilized in the research of renal anemia .

HY-16560S

Camptothecin-d5 Campathecin-d₅; (S)-(+)-Camptothecin-d₅; CPT-d₅	Topoisomerase ADC Cytotoxin MicroRNA Influenza Virus Apoptosis Fungal Antibiotic	Infection Cancer
Camptothecin-d₅ is the deuterium labeled Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM[1]. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells[2][3].

HY-44809

Izilendustat	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease Inflammation/Immunology
Izilendustat is a potent inhibitor of prolyl hydroxylase which can stabilize hypoxia inducible factor- 1 alpha (HIF- lα) and hypoxia inducible factor-2 (HIF-2). Izilendustat has the potential for researching diseases that relate to the body’s inmmune response like colitis and other inflammatory bowel diseases (extracted from patent WO2011057115A1 and WO2011057121A1) .

HY-17412

Minocycline hydrochloride 35+ Cited Publications	Bacterial Antibiotic HIF/HIF Prolyl-Hydroxylase Apoptosis MDM-2/p53 Potassium Channel Calcium Channel	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Minocycline hydrochloride is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline hydrochloride is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline hydrochloride shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline hydrochloride reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline hydrochloride inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

HY-17412A

Minocycline	Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase Apoptosis MDM-2/p53 Potassium Channel Calcium Channel	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

HY-112441

Prolyl Hydroxylase inhibitor 1	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Prolyl Hydroxylase inhibitor 1 (Compound 15i) is an orally active hypoxia inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitor with an IC₅₀ of 62.23 nM . Antianemia agent .

HY-18777

KC7F2 15+ Cited Publications	HIF/HIF Prolyl-Hydroxylase	Cancer
KC7F2 is a potent hypoxia inducible factor-1 (HIF-1) pathway inhibitor with an IC₅₀ of 20 μM in LN229-HRE-AP cells, and with potential as a cancer therapy agent .

HY-17412R

Minocycline hydrochloride (Standard)	Bacterial Antibiotic HIF/HIF Prolyl-Hydroxylase Apoptosis MDM-2/p53 Potassium Channel Calcium Channel	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Minocycline (hydrochloride) (Standard) is the analytical standard of Minocycline (hydrochloride). This product is intended for research and analytical applications. Minocycline hydrochloride is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline hydrochloride is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline hydrochloride shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline hydrochloride reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline hydrochloride inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

HY-W654013

Minocycline-d7	Isotope-Labeled Compounds Apoptosis Potassium Channel Antibiotic Bacterial MDM-2/p53 HIF/HIF Prolyl-Hydroxylase Calcium Channel	Infection
Minocycline-d₇ is deuterium labeled Minocycline. Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

HY-18370

HIF-2α-IN-3	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-3, an allosteric inhibitor of **hypoxia inducible factor-2α (HIF-2α), exhibits an IC₅₀ of 0.4 µM and a K_D** of 1.1 µM. Anticancer agent .

HY-136748

HIF-2α-IN-4 1 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-4 is a potent inhibitor of hypoxia inducible factor-2α (HIF-2α) translation, with an IC₅₀ of 5 μM. HIF-2α-IN-4 decreases both constitutive and hypoxia-induced HIF-2α protein expression. HIF-2α-IN-4 links its 5'UTR iron-responsive element to oxygen sensing .

HY-44809A

Izilendustat hydrochloride	HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology Cancer
Izilendustat (hydrochloride) is a potent inhibitor of prolyl hydroxylase which stabilizes hypoxia inducible factor- 1 alpha (HIF- lα), as well as hypoxia inducible factor-2 (HIF-2). Izilendustat (hydrochloride) has the potential for the research of HIF- lα related diseases including Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, anemia, colitis, and other inflammatory bowel diseases (extracted from patent WO2011057115A1/WO2011057112A1/WO2011057121A1) .

HY-16187

EL-102	HIF/HIF Prolyl-Hydroxylase Apoptosis	Cancer
EL-102 is a hypoxia-induced factor 1 (Hif1α) inhibitor. EL-102 induces apoptosis, inhibits tubulin polymerisation and shows activities against prostate cancer. EL-102 can be used for the research of cancer .

HY-161660

DS44470011	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease Metabolic Disease
DS44470011 is a hypoxia-inducing factor prolyl hydroxylase (HIF-PHD) inhibitor. DS44470011 has oral activity. DS44470011 promotes cell release of erythropoietin (EPO). DS44470011 can be used in the research of renal anemia .

HY-124875

Arylsulfonamide 64B HIF inhibitor 64B	HIF/HIF Prolyl-Hydroxylase	Neurological Disease
Arylsulfonamide 64B (HIF inhibitor 64B) is an inhibitor of the **hypoxia-induced factor (HIF)*. Arylsulfonamide 64B inhibits* hypoxia/HIF-induced expression of c-Met and CXCR4 and reduces primary tumor growth and metastasis of uveal melanoma mouse model .****

HY-155721

22-(4′-py)-JA 22-(4′-Pyridinecarbonyl) jorunnamycin A	Akt mTOR	Cancer
22-(4′-py)-JA is a semisynthetic derivative of junamycin A (JA) that can be isolated from the Thai blue sponge (Xestospongia sp.). 22-(4′-py)-JA has antimetastatic activity and can inhibit AKT/mTOR/p70S6K signaling. 22-(4′-py)-JA inhibits tumor cell invasion and tube formation in human umbilical vein endothelial cells (HUVEC), downregulates metalloproteinases (MMP-2 and MMP-9), hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor (VEGF). 22-(4′-py)-JA has potent anticancer activity against non-small cell lung cancer (NSCLC) .

Cat. No.	Product Name	Target	Research Area

HY-P10221A

Cyclo(CKLIIF) TFA	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CKLIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 2.6 and 2.2 μM, respectively .

HY-P10426

cyclo(CLLFVY)	HIF/HIF Prolyl-Hydroxylase VEGFR	Cancer
cyclo(CLLFVY) is an inhibitor for **hypoxia inducible factor-1 (HIF-1), with IC₅₀** of 19 μM (in U2OS) and 16 μM (in MCF-7). cyclo(CLLFVY) binds to the PAS-B domain of HIF-1α, inhibits HIF-1 dimerization and transcriptional activity. cyclo(CLLFVY) downregulates the expression of hypoxia response genes, such as VEGF and CAIX, exhibits antitumor against the HIF-1 associated cancers .

HY-P10223

Cyclo(CRVIIF)	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CRVIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 65 and 123 μM, respectively .

HY-P10222

Cyclo(CRLLIF)	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CRLLIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 14.5 and 10.2 μM, respectively .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B2171A

Carubicin hydrochloride Carminomycin hydrochloride; Carminomicin I hydrochloride	Infection Quinones Microorganisms Classification of Application Fields Anthraquinones Source classification Phenols Polyphenols Disease Research Fields	Apoptosis
Carubicin hydrochloride is a microbially-derived compound. Carubicin hydrochloride is an effective inhibitor of VHL-defective (VHL−/−) CCRCC cell proliferation. Carubicin hydrochloride also induces apoptosis by a mechanism independent of p53 or hypoxia-inducible factor HIF2. Carubicin hydrochloride has the potential for the research of cancer diseases .

HY-16560

Camptothecin 35+ Cited Publications Campathecin; (S)-(+)-Camptothecin; CPT	Infection Structural Classification Alkaloids Classification of Application Fields Quinoline Alkaloids Camptotheca acuminata Decne. Nyssaceae Plants Disease Research Fields	Topoisomerase ADC Cytotoxin MicroRNA Influenza Virus Apoptosis Fungal Antibiotic
Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM . Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells .

HY-N12041

Axl-IN-16	Structural Classification Natural Products Microorganisms Source classification	TAM Receptor HIF/HIF Prolyl-Hydroxylase
Axl-IN-16 is a dual inhibitor of Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression .

HY-N10330

7-Hydroxyneolamellarin A	Structural Classification Animals Source classification Phenols	HIF/HIF Prolyl-Hydroxylase VEGFR
7-Hydroxyneolamellarin A is a natural product that could be derived from sponge Dendrilla nigra. 7-Hydroxyneolamellarin A is a potent hypoxia-inducible factor-1α (HIF-1α) inhibitor. 7-Hydroxyneolamellarin A attenuates the accumulation of hypoxia-inducible factor-1α (HIF-1α) protein and inhibits vascular epidermal growth factor (VEGF) transcriptional activity. 7-Hydroxyneolamellarin A can be used in research of cancer .

HY-B2171

Carubicin Carminomycin; Carminomicin I	Infection Quinones Microorganisms Classification of Application Fields Anthraquinones Source classification Phenols Polyphenols Disease Research Fields	Apoptosis
Carubicin (Carminomycin) is a microbially-derived compound. Carubicin is an effective inhibitor of VHL-defective (VHL−/−) CCRCC cell proliferation. Carubicin also induces apoptosis by a mechanism independent of p53 or hypoxia-inducible factor HIF2. Carubicin has the potential for the research of cancer diseases .

Cat. No.	Product Name	Chemical Structure

HY-13426S

Roxadustat-d5
Roxadustat-d₅ is deuterium labeled Roxadustat. Roxadustat is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin[1].

HY-16560S

Camptothecin-d5

Camptothecin-d₅ is the deuterium labeled Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM[1]. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells[2][3].

HY-W654013

Minocycline-d7

Minocycline-d₇ is deuterium labeled Minocycline. Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks